No Data
Jiangsu Lianhuan Pharmaceutical (600513.SH): The clinical trial for the new Class 1 drug LH-1801 tablets in combination with metformin has completed subject enrollment in Phase III.
On January 20, Gelonghui reported that Jiangsu Lianhuan Pharmaceutical (600513.SH) announced the completion of subject enrollment for the Phase III clinical trial of the new drug LH-1801 tablets in combination with metformin. LH-1801 tablets are a novel SGLT2 inhibitor developed in collaboration with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, as a new anti-diabetic drug with independent intellectual property rights in China, showing good in vivo blood sugar-lowering effects, indicated for Type 2 diabetes.
Jiangsu Lianhuan Pharmaceutical (SHSE:600513) Stock Performs Better Than Its Underlying Earnings Growth Over Last Five Years
Lianhuan Pharma Gets Good Manufacturing Practice Certificates for Three Products
Jiangsu Lianhuan Pharmaceutical (600513.SH): received the Pharmaceutical GMP compliance inspection results.
On December 23, according to Gelonghui, Jiangsu Lianhuan Pharmaceutical (600513.SH) announced that it received the "Drug GMP Compliance Inspection Result Notification" from the Jiangsu Provincial Drug Administration website. The scope of inspection includes: Active Pharmaceutical Ingredient [sacubitril/valsartan sodium, Workshop 2, C7-H1 production line (hydrogenation), C5-H1 production line (esterification), C5-H2 production line (acylation), No. 8 fine package (co-crystal)]; Oral solution [Workshop 3, Production line 2 (oral solution)]; Tablets [antitumor drugs, Workshop 3, Tablet (antitumor) production line]. According to the "Drug Administration Law" and "Drug Production Supervision Management"
China Approves Jiangsu Lianhuan Pharmaceutical's Heart Failure Treatment Injection
Jiangsu Lianhuan Pharmaceutical (600513.SH): Digoxin injection obtained pharmaceutical registration certificate.
On December 2, GELONGHUI reported that Jiangsu Lianhuan Pharmaceutical (600513.SH) announced that it recently received the 'Pharmaceutical Registration Certificate' approved and issued by the National Medical Products Administration, with the pharmaceutical name: Digoxin Injection. Digoxin Injection can be used to treat adults with mild to moderate heart failure, increase myocardial contractility in pediatric patients with heart failure, and control ventricular rate in patients with atrial fibrillation, atrial flutter with rapid ventricular rates, and supraventricular tachycardia.
Why Jiangsu Lianhuan Pharmaceutical's (SHSE:600513) Shaky Earnings Are Just The Beginning Of Its Problems
